Last reviewed · How we verify
NCT07091318
CBTi for the Treatment of Insomnia in Type 1 Diabetes
EARLY_PHASE1 trial testing Sleep quality improvement therapy in Diabetes Mellitus Type 1 in 15 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | University of Illinois at Chicago |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 15 |
| Start date | 1 December 2025 |
| Primary completion | 31 December 2026 |
| Estimated completion | 30 June 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Sleep quality improvement therapy
- Healthy Living
Conditions studied
- Diabetes Mellitus Type 1 — all drugs for Diabetes Mellitus Type 1 →
- Insomnia — all drugs for Insomnia →
Sponsor
University of Illinois at Chicago
Who can join
Adults 18 to 65, any sex, with Diabetes Mellitus Type 1 or Insomnia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study is to learn if treating insomnia with a therapy intervention in people with type 1 diabetes will help to better control sugar levels, sleep, and quality of life. The questions this study aims to answer include: Will this intervention help the insomnia symptoms? Will obtaining better sleep aid in the control of diabetes through measures like sugar levels? Will the intervention help with quality of life factors like mood and fatigue? Researchers will compare participants receiving the therapy intervention for sleep with those in the "healthy living" intervention to see if the outcomes are different based on the treatment. Participants in the therapy intervention group will: * meet virtually with a therapist for 8 sessions via Zoom. Once a week for the first 4 weeks and then every other week for the last 4 sessions. Participants in the healthy living group will: * receive weekly health education emails * receive brief weekly calls from a coach to answer any questions Participants, regardless of intervention, over the 12 week study period will: * monitor their sleep for 2 weeks through a sleep-monitoring watch * share their continuous glucose monitoring data throughout the study * answer questionnaires prior to the intervention, halfway through the intervention and then after the intervention * attend 3 in person office visits
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07091318
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabetes Mellitus Type 1
Currently open trials in the same condition.
- NCT07320495 — Efficacy and Safety of the APGO Algorithm for Automated Insulin Delivery · NA · recruiting
- NCT06936280 — Type 1 Diabetes and Diabetes Distress · NA · recruiting
Other University of Illinois at Chicago trials
Trials by the same sponsor.
- NCT07498322 — Chicago Data-driven Opioid Use Disorder Screening, Engagement, Treatment and Planning System · NA · not yet recruiting
- NCT07387705 — On Track for Wellness (OTW) Stepped Wedge Cluster Randomized Trial · Phase 1 · not yet recruiting
- NCT07504120 — The Effect of Remotely Delivered Pilates on Physical , and Psychological Outcomes in Individuals With Multiple Sclerosis · NA · not yet recruiting
- NCT07160582 — Cognitive-Motor Training for AD/ADRD Prevention · NA · not yet recruiting
- NCT07498348 — Apple Watch Evaluation of Endodontics Occupational Stress · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07091318 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Illinois at Chicago
- Last refreshed: 22 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07091318.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing